BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/24/2023 1:35:50 PM | Browse: 202 | Download: 423
 |
Received |
|
2022-10-06 09:53 |
|
Peer-Review Started |
|
2022-10-06 09:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-12-12 10:44 |
|
Revised |
|
2022-12-17 23:31 |
|
Second Decision |
|
2023-02-08 03:31 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-02-08 08:31 |
|
Articles in Press |
|
2023-02-08 08:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-02-10 06:14 |
|
Publish the Manuscript Online |
|
2023-02-24 13:35 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Michael Kram |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michael Kram, FACG, Staff Physician, Department of Gastroenterology, Bon Secours Health System Inc, 6 Suhl Lane, Monsey, NY 10952, United States. michaelkrammd@gmail.com |
| Key Words |
Galectin-3 inhibition; Non-alcoholic fatty liver disease; Fibrosis; Macrophage |
| Core Tip |
Galectin-3 inhibition is being advanced as a therapy for liver fibrosis and cirrhosis. Clinicians need to understand the rationale behind this new advance. This minireview will highlight the basic science, as well as recent advances in the field, including the concept of the “galectin-3 fibrosome” and the galectin-3 positive macrophage that enters the liver from the peripheral circulation in the setting of nonalcoholic fatty liver disease. Galectin-3 appears to be central to the non-alcoholic steatohepatitis fibrosis process, and inhibition of galectin-3 is imperative to curtail liver fibrosis. |
| Publish Date |
2023-02-24 13:35 |
| Citation |
Kram M. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World J Hepatol 2023; 15(2): 201-207 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i2/201.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i2.201 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
